OAT PINs and DINs

On this page

• Regular benefit OAT
  • Methadone
  • Buprenorphine/naloxone, Sublocade^® and Kadian^®
• Non-benefit OAT
  • Methadone
  • Suboxone^®
• Transaction medication updates (TMU)

These tables provide product identification numbers (PINs) and drug identification numbers (DINs) for PharmaCare claims for opioid agonist treatment (OAT).

For information about PINs for transaction medication updates (TMUs) for clinicians at outpatient health facilities, visit IIMOAT records in PharmaNet.

PINs are for OAT claims only. If a prescription is for pain, enter the transaction in PharmaNet with the corresponding DIN. Do not use OAT PINs for pain indications.

As of June 6, 2023, regular benefit OAT is covered under plans B, C, G and Z. Non-benefit OAT is covered under plans B, C, G, W and Z. ​

​Interaction fees

PharmaCare pays an interaction fee to pharmacies that are a) enrolled in the OAT provider sub-class; and b) dispensing methadone with direct interaction. Only witnessed ingestion of methadone is eligible for the fee.

Exceptional Plan Z coverage

Exceptional Plan Z coverage of OAT is available to people living in B.C. who are not yet fully enrolled in MSP. See Exceptional Plan Z coverage for OAT on the Plan Z web page.

Potential coverage issues for non-benefit OAT Special Authority

After June 6, 2023, patients should receive 100% coverage for non-benefit OAT if they have active exceptional SA in place. Pharmacists should be aware that patients with exceptional SA for non-benefit OAT (i.e., Methadose^® sugar-free/dye-free, compounded methadone, Suboxone^® 12 mg and 16 mg SL tabs, Suboxone^® film) may experience a change from 100% coverage to partial or no coverage at the pharmacy, despite having an active SA approval. This could happen, for instance, following an income review or January 1 deductible update for patients covered by Fair PharmaCare. This is due to the technicalities of entering SAs to cover non-benefit OAT under Plan Z.

Pharmacists and prescribers should call the HIBC Help Desk if they believe that someone with an SA for non-benefit OAT is not receiving the appropriate coverage. Help Desk staff will determine whether the SA is active and, if so, will contact the SA team to determine coverage issues and re-instatement. If the SA has indeed expired, the prescriber will need to submit a new SA request.

Entering nurse-prescribed OAT dispenses in PharmaNet

Pharmacists are expected to dispense OAT prescriptions written by certified registered nurses (RNs) and registered psychiatric nurses (RPNs). RNs and RPNs can prescribe buprenorphine/naloxone, methadone, slow-release oral morphine (Kadian^®), and certain Schedule I or II drugs. As of December 1, 2023, nurses must be certified through the BC College of Nurses and Midwives.

When dispensing, pharmacists must verify that the nurse is identified as a prescriber in PharmaNet. The ID reference code for prescribing nurses will be Y9 or R9. The best way to confirm is to search for the practitioner in PharmaNet by first and last name, as this will show multiple records if they exist. Select the most recent record only.

If searching by ID reference code and practitioner ID, search using both the prescribing and non-prescribing codes and, if multiple records are found, select the most current only.

Reference ID codes

	Prescribing ID reference code	Non-prescribing ID reference code (do not fill)
RNs	R9	RX
RPNs	Y9	YX

Note: You may see both ID reference codes for one nurse. Do not fill if the prescribing reference code is not the most current record. If you have any questions, please call the PharmaNet Help Desk at 604-682-7120 (Lower Mainland) or 1-800-554-0225 (rest of B.C.). 

Regular benefit OAT

Methadone

Methadone claim submission requirements

• Claim quantity must be submitted as total mL
• SIG must include dose in mg and mL, e.g., "Take 5 mL (50 mg) once daily."
• SIG must include the start and end dates of the prescription.
• Carries must be claimed as single multiple-day supply for drug cost, plus a single dispensing fee.
• Split doses must be claimed as a single multiple-dose claim for drug cost, plus a single dispensing fee.
• Maximum one dispensing fee and one interaction fee per patient per day.

For information on the Methadone Maintenance Payment Program, visit Methadone Maintenance Payment Program — Section 8.8, PharmaCare Policy Manual.

 Regular benefit – methadone (cherry)

Methadose™ 10 mg/mL (cherry) DIN 2394596	PIN for OAT	Plan coverage
Methadose 10 mg/mL (cherry) - direct interaction	66999997	Plans B, C, G, and Z
Methadose 10 mg/mL (cherry) - no direct interaction	66999998
Methadose 10 mg/mL (cherry) - direct interaction with delivery	66999999
Methadose 10 mg/mL (cherry) - no direct interaction with delivery	67000000

Regular benefit – methadone (unflavoured)

Metadol-D™ 10 mg/mL (unflavoured) DIN 2244290	PIN for OAT	Plan coverage
Metadol-D 10 mg/mL (unflavoured) - direct interaction	67000005	Plans B, C, G, and Z
Metadol-D 10 mg/mL (unflavoured) - no direct interaction	67000006
Metadol-D 10 mg/mL (unflavoured) - direct interaction with delivery	67000007
Metadol-D 10 mg/mL (unflavoured) - no direct interaction with delivery	67000008

Buprenorphine/naloxone, Sublocade^® and Kadian^® 

Regular benefit – Buprenorphine/naloxone, Sublocade^® and Kadian^®

Buprenorphine/naloxone, Sublocade® and Kadian®	DIN/PIN for OAT	Plan coverage	Claim submission requirements
buprenorphine/naloxone SL - 2 mg/0.5 mg generics	ACT 02453908	Plans B, C, G, and Z No interaction fee paid for witnessed ingestion	Claim quantity is number of tablets SIG should include start and end dates as best practice (not mandatory)
	PMS 02424851
buprenorphine/naloxone SL - 8 mg/2 mg generics	ACT 02453916
	PMS 02424878
Kadian slow-release oral morphine 10 mg capsule	22123349 (PIN)	Plans B, C, G, and Z No interaction fee paid for witnessed ingestion	Use PINs if for OAT Claim quantity is number of capsules SIG should include start and end dates as best practice (not mandatory).
Kadian slow-release oral morphine 20 mg capsule	22123346 (PIN)
Kadian slow-release oral morphine 50 mg capsule	22123347 (PIN)
Kadian slow-release oral morphine 100 mg capsule	22123348 (PIN)
Sublocade 100 mg/0.5 SOLER SYR	02483084	Plans B, C, G, and Z. Eligible for drug administration fee	Claim quantity is number of syringes SIG should include start and end dates as best practice (not mandatory)
Sublocade 300 mg/1.5 SOLER SYR	02483092

Non-benefit OAT

Methadone

Non-benefit – methadone (unflavoured, sugar-free)

Methadose™ 10 mg/mL (unflavoured, sugar-free) DIN 2394618	PIN for OAT	Plan coverage
Methadose 10 mg/mL (sugar-free) - direct interaction	67000001	Non-benefit. Exceptional Special Authority coverage required under Plan B, C, G, W and Z.
Methadose 10 mg/mL (sugar-free) - no direct interaction	67000002
Methadose 10 mg/mL (sugar-free) - direct interaction with delivery	67000003
Methadose 10 mg/mL (sugar-free) - no direct interaction with delivery	67000004

Non-benefit – compounded methadone

Compounded methadone 10 mg/mL	PIN for OAT	Plan coverage
Compounded methadone 10 mg/mL - direct interaction	67000013	Last-resort, exceptional coverage available with Special Authority Dispensing pharmacies must order compounded methadone from the central compounding pharmacy For more information please visit the BCCSU compounded methadone bulletin
Compounded methadone 10 mg/mL - direct interaction with delivery	67000014
Compounded methadone 10 mg/mL - no direct interaction	67000016
Compounded methadone 10 mg/mL - no direct interaction with delivery	67000015

Suboxone^®

Partial benefit / Non-benefit – Suboxone^®

Suboxone®	DIN/PIN for OAT	Plan coverage	Claim submission requirements
Partial benefit
Suboxone buprenorphine/naloxone - 2 mg/0.5 mg SL	02295695	Partial benefit under Plan B, C, G and Z. No interaction fee paid for witnessed ingestion.	Claim quantity is number of tablets SIG should include start and end dates as best practice (not mandatory)
Suboxone buprenorphine/naloxone - 8 mg/2 mg SL	02295709
Non-benefit
Suboxone buprenorphine/naloxone - 12 mg/3 mg SL	02468085	Exceptional Special Authority coverage required under plans Plan B, C, G, W and Z. No interaction fee paid for witnessed ingestion.
Suboxone buprenorphine/naloxone - 16 mg/4 mg SL	02468093

TMU PINs – transaction medication updates

Not for pharmacy entry. For pharmacist information only. These PINS are for clinicians at outpatient health facilities to input. See IIMOAT records in PharmaNet for more details. 

Situation	PIN
Clinic (ward) stock dose	66128342
missed dose	66128343
dose increased at clinic visit	66128344
dose decreased at clinic visit	66128345
buprenorphine/naloxone induction doses	66128346